Overview

GANfort® in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Are Insufficiently Responsive to Monotherapy

Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
This is an observational study of patients diagnosed with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) who are insufficiently responsive to monotherapy and who are prescribed GANfort® (fixed combination of 0.3 mg bimatoprost and 5 mg timolol) by their physician.
Details
Lead Sponsor:
Allergan
Treatments:
Bimatoprost
Timolol